LPOXY Therapeutics to Attend BIO Partnering @ JPM Week 2025
January 13–16, 2025, at the San Francisco Marriott Marquis in San Francisco, CA.
Platte City, MO – January 2, 2025 -- LPOXY Therapeutics, a biotechnology company committed to preventing bacterial infections, including Clostridioides difficile, today announced its participation in BIO Partnering @ JPM Week 2025, taking place January 13–16, 2025, at the San Francisco Marriott Marquis in San Francisco, CA.
The BIO Partnering @ JPM Week event provides a unique platform for biotech and life sciences companies to engage with investors, pharmaceutical executives, and potential partners through one-on-one meetings and networking opportunities.
“BIO Partnering @ JPM Week is an invaluable opportunity for us to connect with investors and strategic partners who share our commitment to addressing the global healthcare burden posed by bacterial infections,” said Larry Sutton, MD, PhD, CEO of LPOXY Therapeutics. “C. difficile infections alone affect a half million people in the U.S. annually and result in more than $5 billion in direct healthcare costs. The need for innovative prevention strategies is urgent, and LPOXY’s approach not only addresses this critical unmet need but also represents a compelling market opportunity for investors and collaborators looking to make a meaningful impact in healthcare.”
About BIO Partnering @ JPM Week:
BIO Partnering @ JPM Week, hosted by the Biotechnology Innovation Organization (BIO), is a premier networking event held concurrently with the JP Morgan Healthcare Conference. It facilitates partnering meetings and strategic conversations between biotech innovators, pharmaceutical leaders, and life sciences investors from around the globe.
About LPOXY Therapeutics:
LPOXY Therapeutics is a biotechnology company focused on the prevention of bacterial infections, with a primary emphasis on tackling C. difficile, a leading cause of healthcare-associated infections. Our innovative platform is designed to reduce the healthcare and economic burden associated with bacterial infections, particularly in vulnerable patient populations. With a strategic focus on impactful clinical development, LPOXY aims to deliver significant value to patients and stakeholders alike.
For more information about LPOXY Therapeutics and its development programs, please contact:
Larry Sutton, MD, PhD
CEO, LPOXY Therapeutics Inc.
Phone: +1 (816) 200-0513
Email: larry@lpoxy.com
Visit our website at www.lpoxy.com for additional details and updates.